GL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Globe Life is not a clear buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The business is fundamentally improving and analysts remain constructive, but the stock is already near resistance, sentiment from insiders/hedge funds is negative, and there is no strong proprietary buy signal today. For an impatient buyer, this is better treated as a hold than an immediate purchase.
GL is in a bullish medium-term trend with SMA_5 > SMA_20 > SMA_200 and MACD histogram still positive at 0.236, though it is contracting, which suggests momentum is slowing rather than accelerating. RSI_6 at 75.435 is elevated, indicating the stock is extended short term. Pre-market price is 154.3, sitting just below R1 at 154.634 and close to resistance at 156.925. That makes the current entry less attractive for a fast decision, even though the broader trend remains positive.
Q1 2026 results were solid: revenue rose 5.35% YoY, net income rose 6.27% YoY, and EPS increased 12.62% YoY. Analysts have been raising targets, with Keefe Bruyette moving to $180 and Truist to $185 after a Q1 earnings beat and guidance for low-teens net sales growth at American Income. The company also declared a quarterly dividend of $0.33 per share, supporting the long-term income case.
Hedge funds are actively selling, with selling up 1440.51% over the last quarter, which is a meaningful negative sentiment signal. Two insiders recently disclosed sizable planned sales: James Matt Darden for about $7.96 million and Michael C. Majors for about $5.24 million. The stock trend model also implies weaker near-term returns, with a 60% chance of -0.36% next day, -2.54% next week, and -7.5% next month. No recent congress trading data is available.
In Q1 2026, Globe Life showed healthy growth trends. Revenue increased to $1.56 billion, up 5.35% YoY, net income rose to $270.5 million, up 6.27% YoY, and EPS increased to 3.39, up 12.62% YoY. This is a positive latest-quarter season and shows improving profitability, which supports the long-term thesis.
Wall Street remains mostly bullish. Recent analyst actions include Keefe Bruyette raising its target to $180 with an Outperform rating, Truist raising to $185 with a Buy rating, Texas Capital initiating at Buy with $170, Wells Fargo raising to $171 with Overweight, and JPMorgan raising to $181 with Overweight. The main pro view is improving growth, better free cash flow conversion, and attractive valuation; the main con view is rising competition, balance sheet complexity, and some fading macro tailwinds.
